GT, 76, takes metformin 1,000 mg twice daily. Her eGFR has fallen over a year from 52 to 26 mL/min/1.73 m2. Which of the following is the most appropriate recommendation about her metformin?
The metformin product monograph and Diabetes Canada guidance contraindicate metformin when eGFR is below 30 mL/min because of the risk of lactic acidosis, with dose reduction and caution between 30 and 60. GT's eGFR of 26 means metformin should be stopped and her therapy reviewed. Metformin does not protect the kidneys, and switching formulation does not change the renal risk. Source: Metformin hydrochloride product monograph, Contraindications: eGFR < 30 mL/min (DPD, checked 2026); Diabetes Canada CPG, ch. 13 Pharmacologic glycemic management of type 2 diabetes (2018; 2024 update, Can J Diabetes 2024;48:415).
Continuing full-dose metformin as kidney function declines.
Practice more PEBC MCQ Diabetes, Thyroid, Bone & Hormones questions
Exam-style questions with worked answers, then full timed mocks. Free to start.
Build a daily practice habit — a few exam-style questions a day, with worked answers. Free to start.
Start practicing →Original practice material written to the public PEBC blueprint; not a past or real exam question. Not affiliated with or endorsed by The Pharmacy Examining Board of Canada (PEBC). Educational practice material for exam preparation only. Not medical advice and not a substitute for current product monographs, clinical guidelines or professional judgement. Questions have not yet been reviewed by a licensed pharmacist.